1st Translational Research E-Conference: Chronic Lymphocytic Leukaemia
November 16-19, 2020
Chairs: Jennifer Brown (Boston), Paolo Ghia (Milan), Michael Hallek (Cologne)

This program is presented according to Central European Time (CET).
Please check the corresponding hours in your time zone.

Monday, November 16, 2020

13:50-14:00  Welcome

SESSION I – The genomic and epigenomic landscape of CLL and clinical consequences
Chairs: Jennifer Brown (Boston), Christopher Oakes (Columbus)

14:00-14:05  Introduction
Jennifer Brown (Boston)
Christopher Oakes (Columbus)

14:05-14:20  Genetic predisposition
Jennifer Brown (Boston)

14:20-14:35  Genetic landscape
Cathy Wu (Boston)

14:35-14:50  Ibrutinib resistance
Jennifer Woyach (Colombus)

14:50-15:05  Epigenetic landscape
Christopher Oakes (Columbus)

15:05-15:20  Risk stratification in CLL
Antonio Cuneo (Ferrara)

15:20-15:50  General Discussion

SESSION II – The role of BCR activation and signalling for CLL
Chairs: Paolo Ghia (Milan), Kostas Stamatopoulos (Thessaloniki)

15:50-15:55  Introduction
Paolo Ghia (Milan)
Kostas Stamatopoulos (Thessaloniki)

15:55-16:10  BCR isotypes/autonomous signalling
Hassan Jumaa (Ulm)

16:10-16:25  The latest news on stereotypes
Kostas Stamatopoulos (Thessaloniki)

16:25-16:40  Novel BCR targets
Andrew Steele (Southampton)

16:40-16:55  Next generation BTK inhibitors (covalent/non-covalent?)
Anthony Mato (New York)

SHORT ORAL COMMUNICATION

16:55-17:02  Mutational landscape of CLL mice models
overexpressing aid identify proliferative-associated
tumor genes involved in leukemic progression
Pablo Oppezzo (Montevideo)

17:02- 17:32  General discussion
17:35-18:35  Clinical Poster Walk  
Leaders: Matthew Davids (Boston), Alessandra Tedeschi (Milan)

18:35-20:30  Dinner break. BUT do not forget to come back for....

SESSION III – Therapeutic options for CLL  
Chairs: Alain Delmer (Reims), Michael Hallek (Cologne)

20:30-20:35  Introduction
            Alain Delmer (Reims)  
            Michael Hallek (Cologne)

20:35-20:50  Ibrutinib for everybody
            Jennifer Woyach (Columbus)

20:50-21:05  Ibrutinib for a small subgroup only
            Florence Cymbalista (Bobigny)

21:05-21:20  MURANO and MRD
            John Seymour (Melbourne)

21:20-21:35  CLL14 update
            Kirsten Fischer (Cologne)

SHORT ORAL COMMUNICATION

21:35-21:42  Neddylation pathway regulates treg differentiation  
            and T-cell function in Chronic Lymphocytic Leukemia  
            ex vivo and murine in vivo studies
            Scott Best (Portland)

21:42-22:12  General Discussion

Tuesday, November 17, 2020

13:00-14:00  Simultaneous Lunchtime Meet the Expert sessions

1. Prognostic and predictive markers  Barbara Eichhorst (Cologne)/Loic Ysebaert (Toulouse)
2. First line therapy: continuous or time limited treatment?  Michael Hallek (Cologne)/Alessandra Tedeschi (Milan)

SESSION IV – Long term follow up of clinical trials versus real world data (Outside Clinical Trials data-OCT)  
Chair: Jennifer Woyach (Columbus)

14:05-14:10  Introduction  Jennifer Woyach (Columbus)

14:10-14:25  Ibrutinib trials  Alessandra Tedeschi (Milan)

14:25-14:40  Ibrutinib real world  Loïc Ysebaert (Toulouse)

14:40-14:55  Venetoclax trials  Matthew Davids (Boston)

14:55-15:10  Venetoclax / PI3K real world  Lindsey Roeker (New York)

SHORT ORAL COMMUNICATION

15:10-15:17  Sequential treatment with bendamustine, obinutuzumab (GA101) and ibrutinib in Chronic Lymphocytic Leukemia:  
            final results of the CLL2-BIG trial of the German  
            CLL study group (GCLLSG)
            Julia von Tresckow (Essen)

15:17-15:45  General discussion
15:50-16:50  **SATELLITE SYMPOSIUM:**
Utilization of MRD assessment in the clinical management of CLL patients

*Chair: Barbara Eichhorst (Cologne)*
*Speakers: Barbara Eichhorst (Cologne), Lanny Kirsch (Seattle), Anna Schuh (Oxford)*

_This symposium is organised and funded by Adaptive Biotechnologies._

16:50-17:50  **Meet the Expert session**
Resistance to ibrutinib: what to do  
Jennifer Brown (Boston)/Anna Schuh (Oxford)

16:50-17:50  **Biology Poster Walk:**
*Leaders: Alexey Danilov (Duarte), Davide Rossi (Bellinzona)*

**Wednesday, November 18, 2020**

**SESSION V – The increasing role of the leukaemic microenvironment**
*Chairs: Silvia Deaglio (Turin), Adrian Wiestner (Bethesda)*

14:30-14:35  Introduction  
Silvia Deaglio (Turin)
Adrian Wiestner (Bethesda)

14:35-14:50  Role of stromal cells  
Andrea Brendolan (Milan)

14:50-15:05  Hypoxia, metabolic reprogramming and immunosuppression occurring in CLL niche  
Silvia Deaglio (Turin)

15:05-15:20  Role of T cells  
Arnon Kater (Amsterdam)

15:20-15:35  Immunomodulatory effects of kinase inhibitors  
Adrian Wiestner (Bethesda)

**SHORT ORAL COMMUNICATION**

15:35-15:42  *Expansion of antitumor cytotoxic CD8+ T cells in CLL patients treated with ibrutinib*  
Maria Joao Baptista (Badalona)

15:42-16:12  General discussion

**SESSION VI – Therapeutic options 2: The use of cellular and non-cellular immunotherapies in CLL**
*Chairs: Matthew Davids (Boston), Peter Dreger (Heidelberg)*

16:15-16:20  Introduction  
Matthew Davids (Boston)
Peter Dreger (Heidelberg)

16:20-16:35  Next generation PI3K inhibitors  
Peter Hillmen (Leeds)

16:35-16:50  Novel inhibitors at preclinical level (MCL1 & CDK inhibitors)  
Alexey Danilov (Duarte)

16:50-17:05  Mechanistic effects of BH3 Mimetics in CLL  
Eric Eldering (Amsterdam)
17:05-17:20  CAR-T cells  Stephen Schuster (Philadelphia)
17:20-17:35  Allo-transplant  Peter Dreger (Heidelberg)
17:35-18:05  General discussion

SESSION VII – Efficacy through safety
Chairs: Barbara Eichhorst (Cologne), Javid Moslehi (Nashville)

18:05-18:10  Introduction  Barbara Eichhorst (Cologne)
              Javid Moslehi (Nashville)
18:10-18:25  Cardiologist  Javid Moslehi (Nashville)
18:25-18:40  Dermatologist  Nicole LeBoeuf (Boston)
18:40-18:55  Infectious diseases  Michele Bartoletti (Bologna)
18:55-19:10  Gastroenterology  Stefano Fagioli (Bergamo)
19:10-19:40  General discussion

Thursday, November 19, 2020

12:00-13:00  Simultaneous Lunchtime Meet the Expert sessions

1.  Treatment of relapsed CLL  Paolo Ghia (Milan)/Barbara Eichhorst (Cologne)
2.  Management of novel drugs - side effects  Carol Moreno (Barcelona)/Davide Rossi (Bellinzona)
3.  MRD assessment  Andrew Rawstron (Leeds)/Arnon Kater (Amsterdam)

SESSION VIII – Clonal heterogeneity, clonal evolution and mechanisms of drug resistance
Chairs: Davide Rossi (Bellinzona), John Seymour (Melbourne)

13:00-13:05  Introduction  Davide Rossi (Bellinzona)
              John Seymour (Melbourne)
13:05-13:20  Clonal evolution  Davide Rossi (Bellinzona)
13:20-13:35  PI3K  Jennifer Brown (Boston)
13:35-13:50  Venetoclax  John Seymour (Melbourne)

SHORT ORAL COMMUNICATIONS

13:50-13:57  Aid-mediated mechanisms of resistance to BCR inhibitors in Chronic Lymphocytic Leukemia (CLL)  Chiara Pighi (Turin)
13:57-14:04  NOTCH2 contributes to venetoclax resistance in Chronic Lymphocytic Leukemia  Stefania Fiorcari (Modena)
14:04-14:35  General discussion
14:35-14:45  Coffee break
SESSION IX – Contrasting therapeutic concepts
Chairs: Jennifer Brown (Boston), Michael Hallek (Cologne)

14:45-14:50  Introduction
Jennifer Brown (Boston)
Michael Hallek (Cologne)

14:50-15:05  MRD as a dynamic endpoint
Peter Hillmen (Leeds)

15:05-15:20  Dynamic risk profiling using serial tumor biomarkers
for personalized outcome prediction in lymphoid
malignancies including CLL
David M. Kurtz (Stanford)

15:20-15:35  Sequential vs combination treatments
William Wierda (Houston)

15:35-15:50  Time limited vs continuous treatments
Barbara Eichhorst (Cologne)

15:50-16:20  General discussion

16:20-16:30  Closing Remarks

MEETING CLOSURE